Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study

Overview

Journal Transplant Cell Ther

Date 2023 Jul 7

PMID 37419326

Authors

Theodros Mamo

Darin Sumstad

Todd E DeFor

Qing Cao

Margaret L MacMillan

Claudio Brunstein

Mark Juckett

David H McKenna

Affiliations

Soon will be listed here.

Abstract

Higher doses of infused nucleated cells (NCs) are associated with improved clinical outcomes in bone marrow transplantation (BMT) recipients. Most clinicians recommend infusing at least 2.0 × 10 NCs/kg. BMT clinicians request a target NC dose, but the harvested NC dose may be below the requested NC dose even before cell processing. We conducted this retrospective study to investigate the quality of bone marrow (BM) harvest and factors that influence infused NC doses at our institution. We also correlated infused NC doses with clinical outcomes. The study population included 347 BMT recipients (median age, 11 years; range, <1 to 75 years) at the University of Minnesota between 2009 and 2019. Underlying diagnoses mainly included 39% malignant and 61% nonmalignant diagnoses. Requested, harvested, and infused NC doses, as well as cell processing data, were obtained from the Cell Therapy Laboratory; clinical outcomes data were obtained from the University of Minnesota BMT Database. BM harvests were facilitated either by our institution (61%) or by the National Marrow Donor Program (39%). Associations of infused doses with baseline characteristics were assessed using the general Wilcoxon test/Pearson's correlation coefficient. The association of infused dose with neutrophil engraftment (absolute neutrophil count >500) by day 42, platelet engraftment (>20,000) by 6 months, acute graft-versus-host disease grade II-IV, and overall survival (OS) at 5 years were evaluated using regression and Kaplan-Meier curves. The median requested NC dose was 3.0 × 10/kg (range, 2 to 8 × 10/kg), and the median harvested and infused NC doses were 4.0 × 10/kg and 3.6 × 10/kg, respectively. Only 7% of donors had a harvested dose below the minimum requested dose. Moreover, the correlation between requested doses and harvested doses was adequate, with a harvested/requested dose ratio <.5 observed in only 5% of harvests. Additionally, the harvest volume and cell processing method were significantly correlated with the infused dose. Harvest volume exceeding the median of 948 mL was related to a significantly lower infused dose (P < .01). Moreover, hydroxyethyl starch (HES)/buffy coat processing (used to reduce RBCs with major ABO incompatibility) led to a significantly lower infused dose (P < .01). Donor age (median, 19 years; range, <1 to-70 years) and sex did not significantly influence the infused dose. Finally, the infused dose was significantly correlated with neutrophil and platelet engraftment (P < .05) but not with 5-year OS (P = .87) or aGVHD (P = .33). In our program's experience, BM harvesting is efficient and meets the requested minimum dose for 93% of recipients. Harvest volume and cell process play significant roles in determining the final infused dose. Minimizing harvest volume and cell processing could lead to increased infused dose and thus improved outcomes. Moreover, a higher infused dose leads to a better rate of neutrophil and platelet engraftment but not to improved OS, which may be linked to the sample size of our study.

References

DSouza A, Fretham C, Lee S, Arora M, Brunner J, Chhabra S . Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26(8):e177-e182. PMC: 7404814. DOI: 10.1016/j.bbmt.2020.04.013. View

Spitzer T, Kim S, Cohen R, Mathews R, Li S, McAfee S . Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplant. 2020; 56(4):983-985. DOI: 10.1038/s41409-020-01143-3. View

Lin D . Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997; 16(8):901-10. DOI: 10.1002/(sici)1097-0258(19970430)16:8<901::aid-sim543>3.0.co;2-m. View

Sierra J, Storer B, Hansen J, Bjerke J, Martin P, Petersdorf E . Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997; 89(11):4226-35. View

Martin P, Li S, Nikiforow S, Alyea 3rd E, Antin J, Armand P . Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016; 101(4):499-505. PMC: 5004400. DOI: 10.3324/haematol.2015.134841. View

Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E . CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the.... Am J Hematol. 2020; 95(8):892-899. DOI: 10.1002/ajh.25826. View

Lee S, Lee M, Lee J, Min Y, Lee K, Cheong J . Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant. 2005; 11(2):122-8. DOI: 10.1016/j.bbmt.2004.11.018. View

Malempati S, Joshi S, Lai S, Braner D, Tegtmeyer K . Videos in clinical medicine. Bone marrow aspiration and biopsy. N Engl J Med. 2009; 361(15):e28. DOI: 10.1056/NEJMvcm0804634. View

Heimfeld S . Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?. Leukemia. 2003; 17(5):856-8. DOI: 10.1038/sj.leu.2402893. View

10.

Remberger M, Torlen J, Ringden O, Engstrom M, Watz E, Uhlin M . Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(5):889-93. DOI: 10.1016/j.bbmt.2015.01.025. View

11.

Rocha V, Labopin M, Gluckman E, Powles R, Arcese W, Bacigalupo A . Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol. 2002; 20(21):4324-30. DOI: 10.1200/JCO.2002.11.058. View

12.

Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2009; 45(2):219-34. DOI: 10.1038/bmt.2009.141. View

13.

Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C . A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?. Bone Marrow Transplant. 2000; 26(5):489-96. DOI: 10.1038/sj.bmt.1702542. View

14.

Dominietto A, Lamparelli T, Raiola A, Van Lint M, Gualandi F, Berisso G . Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002; 100(12):3930-4. DOI: 10.1182/blood-2002-01-0339. View

15.

Prokopishyn N, Logan B, Kiefer D, Sees J, Chitphakdithai P, Ahmed I . The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biol Blood Marrow Transplant. 2019; 25(7):1325-1330. PMC: 6615955. DOI: 10.1016/j.bbmt.2019.01.034. View

16.

Remberger M, Gronvold B, Ali M, Mattsson J, Egeland T, Lundin K . The CD34 Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors. Clin Hematol Int. 2021; 2(2):74-81. PMC: 8432346. DOI: 10.2991/chi.d.200221.001. View

17.

Pelus L, Broxmeyer H . Peripheral blood stem cell mobilization; a look ahead. Curr Stem Cell Rep. 2019; 4(4):273-281. PMC: 6532982. DOI: 10.1007/s40778-018-0141-9. View

18.

Torlen J, Ringden O, Le Rademacher J, Batiwalla M, Chen J, Erkers T . Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014; 20(9):1418-25. PMC: 4127369. DOI: 10.1016/j.bbmt.2014.05.021. View

19.

Pulsipher M, Chitphakdithai P, Logan B, Leitman S, Anderlini P, Klein J . Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009; 114(13):2606-16. PMC: 2756121. DOI: 10.1182/blood-2009-03-208355. View

20.

Goldman J . A special report: bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world--1994 update. The WMDA Executive Committee. Blood. 1994; 84(9):2833-9. View